PRAGUE, Czech Republic — A 0.4-mg/kg bolus dose of tenecteplase (TNKase, Genentech) was associated with functional outcomes and safety similar to those seen with the standard of care, alteplase ...
Collecting and documenting disability status at an Enhancing Oncology Model site: Outcomes of an ASCO Quality Training Project. This is an ASCO Meeting Abstract from the 2025 ASCO Quality Care ...
Switching from alteplase to tenecteplase as the thrombolytic used routinely for acute ischemic stroke is having multiple benefits for one US hospital system. Tenecteplase was developed as a more ...
When treating patients with acute ischemic stroke within 4.5 hours of symptom onset, tenecteplase provides noninferior outcomes compared with alteplase (Activase; Genentech), with similar safety, ...
Alteplase was paid for by the patients, who later received various degrees of reimbursement from the Chinese social security system. In most instances, the patients or their families had to either ...
DALLAS, Feb. 1, 2024 — Compared with the standard clot-busting medication alteplase, the newer clot-buster tenecteplase may offer a safe, effective and simpler way to treat ischemic (clot-caused) ...
Whether the evidence supports wider use of tenecteplase (TNKase; Genentech)—a thrombolytic agent with an indication for acute MI—as an alternative to alteplase (Activase; Genentech) for the treatment ...
Giving the clot-busting medication alteplase at the site of a blocked brain artery after blood clot removal may increase the number of patients who fully recover, according to preliminary ...
LOS ANGELES -- Tenecteplase (TNKase) used off-label as the routine standard for stroke thrombolysis at one Texas stroke network was both feasible and safe, according to the early experience switching ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window DALLAS -- ...
Even after a blood clot is removed from a large artery in the brain via a minimally invasive procedure to treat a clot-caused stroke, delivering the clot-busting medication alteplase to the area may ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results